Investigational drug · Phase 3
HSK39004 Dry Simulant
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for COPD (Chronic Obstructive Pulmonary Disease), Chronic Obstructive Pulmonary Disease (COPD).
Phase 3Last checked: Nov 20, 2026Latest source record: Jun 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "HSK39004 Dry Simulant"
First trial start
2025
Aug 13, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HSK39004 Dry Simulant", any sponsor or status.
Conditions studied
As listed on its trial records.
- COPD (Chronic Obstructive Pulmonary Disease)
- Chronic Obstructive Pulmonary Disease (COPD)
Approved drugs for the same conditions: COPD · Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "HSK39004 Dry Simulant" as an intervention, largest first.
- A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase III Study of HSK39004 Inhalation Powder for the Treatment of COPDPivotal-lookingRecruiting
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT07583849 · 376 participants (planned) · Start May 24, 2026 · Primary completion Sep 30, 2027
Drug: HSK39004 Dry Powder Inhaler Simulant; HSK39004 Dry Powder Inhaler-0.75mg · For: COPD (Chronic Obstructive Pulmonary Disease)
Sites: Beijing, China
- Evaluation of the Safety and Efficacy of HSK39004 Dry Powder Inhaler in Chinese Patients With Chronic Obstructive Pulmonary Disease (COPD)Pivotal-lookingActive, not recruiting
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT07108699 · 180 participants (planned) · Start Aug 13, 2025 · Primary completion Aug 30, 2026
Drug: HSK39004 Dry Powder Inhaler-0.75mg; HSK39004 Dry Powder Inhaler-1.5mg and 1 more · For: Chronic Obstructive Pulmonary Disease (COPD)
Sites: Chengdu, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for COPD (Chronic Obstructive Pulmonary Disease)
- Hemay005Mufemilast, Phosphodiesterase 4 inhibitorsPhase 34 trials
Ganzhou Hemay Pharmaceutical Co., Ltd · Moderate to Severe Ulcerative Colitis, Ulcerative Colitis (UC), COPD (Chronic Obstructive Pulmonary Disease)
- HSK39004 DryPhase 34 trials
Haisco Pharmaceutical Group Co., Ltd. · Chronic Obstructive Lung Disease (COLD), COPD (Chronic Obstructive Pulmonary Disease), Chronic Obstructive Pulmonary Disease (COPD)
- BGF MDI 320BGFPhase 33 trials
AstraZeneca · Asthma, COPD (Chronic Obstructive Pulmonary Disease)
- REGEND001Phase 32 trials
Regend Therapeutics · COPD (Chronic Obstructive Pulmonary Disease), Idiopathic Pulmonary Fibrosis
- WIN378Phase 22 trials
Windward Bio · COPD (Chronic Obstructive Pulmonary Disease), Asthma
- JKN2304Phase 21 trial
Joincare Pharmaceutical Group Industry Co., Ltd · COPD (Chronic Obstructive Pulmonary Disease), COPD
- JKN24011Phase 21 trial
Joincare Pharmaceutical Group Industry Co., Ltd · COPD (Chronic Obstructive Pulmonary Disease)
- JKN2403Phase 21 trial
Joincare Pharmaceutical Group Industry Co., Ltd · COPD (Chronic Obstructive Pulmonary Disease)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.